MedTrace Logo

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

NCT05708677 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2024-06-27

No results posted yet for this study

Summary

A Long-Term Extension Study for Participants Previously Treated with EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Conditions

  • RDEB

Interventions

BIOLOGICAL

EB-101

This is non-interventional and follows patients treated with EB-101

Sponsors & Collaborators

  • Abeona Therapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • Angela Iheanacho, MS · Abeona Therapeutics, Inc

  • Sarah Abdelwahab, MD · Abeona Therapeutics, Inc

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-09
Primary Completion
2036-02-29
Completion
2036-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05708677 on ClinicalTrials.gov